Treatment of benign prostatic enlargement

In September 2023, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedure Guidance (removal, preservation, and reimplantation of ovarian tissue for restoring fertility, transurethral water-jet ablation for lower urinary tract symptoms, cryotherapy for chronic rhinitis), and three Health Technology Evaluations using early value assessment (AI-derived software to analyze chest X-rays for suspected lung cancer, AI technologies to aid contouring for radiotherapy planning, KardiaMobile 6L for adults having antipsychotic medication). Also, two new clinical guidelines were published, and three were updated.

In February 2023, Swedish Medical Technologies Product (MTP) Council announced ongoing horizon scanning within the Orderly introduction framework for medical technologies to be used in benign prostatic hyperplasia. The Dental and Pharmaceutical Benefits Agency (TLV) initiated a theme survey, accepting suggestions until March 31, 2023.

In November 2022, the National Institute for Health and Care Excellence (NICE) published five new Interventional Procedure Guidance (extracorporeal shockwave therapy for calcific tendinopathy in the shoulder, balloon disimpaction of the baby's head at emergency cesarean, percutaneous ultrasound-guided microwave ablation for benign thyroid nodules, ab interno canaloplasty for open-angle glaucoma, tunnelled peritoneal drainage catheter insertion), and two new Medical Technologies Guidance (GreenLight XPS, Optilume). Also, one new clinical guideline was published, and one was updated.

In September 2022, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedure Guidance (removal, preservation and subsequent reimplantation of ovarian tissue, prostatic urethral temporary implant insertion, neurostimulation of lumbar muscles), and one new Medtech Innovation Briefings (iTind). Also, one Medical Technologies Guidance and three Medtech-related clinical guidelines were updated.

In August 2021, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedure Guidance (magnetic resonance therapy for knee osteoarthritis, laparoscopic removal of uterine fibroids with power morcellation, hysteroscopic mechanical tissue removal for uterine fibroids), and six new Medtech Innovation Briefings (PLASMA system with button electrode, Immunoscore, MMprofiler, Patient Status Engine, lung texture analysis, Colli-Pee). Also, five clinical guidelines were published.

In July 2021, the Austrian Institute for Health Technology Assessment (AIHTA) published six new decision support documents and one update to a previous decision support document. The assessed topics included percutaneous left ventricular assist devices, liposuction for surgical therapy of lipoedema, triphasic biomaterial for augmentation of the osteoporotic femoral neck, endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD), allogenic bone screw Shark Screw® in patients with hallux valgus or scaphoid fractures/pseudarthroses, and surgical interventions for the treatment of benign prostatic hyperplasia. The updated decision support document concerned implantable bulking agents for fecal incontinence.